Home > Oncology > ASCO 2020 > Paediatric Cancer > Promising first immunotherapy trial in placental trophoblastic tumours

Promising first immunotherapy trial in placental trophoblastic tumours

Expert
Prof. Benoit You, Lyon University Hospital, France
Conference
ASCO 2020
Trial
Phase 2, TROPHIMMUN
Featured video: Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy: Final outcomes of TROPHIMMUN phase II trial, cohort A.   Chemoresistant patients with a gestational trophoblastic tumour (GTT) responded well to avelumab in the TROPHIMMUN trial, presented by Prof. Benoit You (Lyon University Hospital, France). One patient went on to a normal pregnancy 1 year after treatment, in the first study of its kind in this rare tumour [1]. GTTs are rare tumours developing in the placenta during pregnancy, characterised by high human chorionic gonadotropin (hCG) blood levels. Low-risk patients with GTT receive a standard single-agent treatment (methotrexate or actinomycin-D) to achieve hCG normalisation, which can be obtained in 65-75% of patients. Patient...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on